Abstract
In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Comment
MeSH terms
-
Antineoplastic Agents* / pharmacology
-
Antineoplastic Agents* / therapeutic use
-
Humans
-
Neoplasms* / drug therapy
-
Phthalazines / pharmacology
-
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Substances
-
Antineoplastic Agents
-
Phthalazines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
talazoparib